Portal vein delivery of viral vectors for gene therapy for hemophilia

Methods in Molecular Biology

Volumn 1114, Issue , 2014, Pages 413-426

  Sherman, Alexandra ^a   Schlachterman, Alexander ^b   Cooper, Mario ^a   Merricks, Elizabeth P ^c   Raymer, Robin A ^c   Bellinger, Dwight A ^c   Herzog, Roland W ^a   Nichols, Timothy C ^c  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

AAV; Gene therapy; Liver; Portal vein; Viral vectors

Indexed keywords

ANALGESIC AGENT; BLOOD CLOTTING FACTOR 9; PARVOVIRUS VECTOR; PROCAINE PENICILLIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BALLOON CATHETER; CANINE MODEL; CONTROLLED STUDY; HEMOPHILIA B; LAPAROTOMY; LIVER; LIVER BIOPSY; LIVER CELL; LUNG; MOUSE; MOUSE MODEL; NONHUMAN; PERIPHERAL VEIN; PORTAL VEIN; POSTOPERATIVE ANALGESIA; POSTOPERATIVE PAIN; PRIORITY JOURNAL; SPLEEN; SURGICAL INFECTION; VIRAL GENE THERAPY; ADENO ASSOCIATED VIRUS; BLOOD VOLUME; EXPERIMENTAL DOG; FEMALE; FOLLOW UP; HEMATOCRIT; HYPOTHERMIA; PANCREAS; PLASMA VOLUME; SKIN INCISION; TARGET ORGAN; VIRAL GENE DELIVERY SYSTEM;

ANIMALIA; CANIS FAMILIARIS; MURINAE; MUS;

ADMINISTRATION, INTRAVENOUS; ANIMALS; DEPENDOVIRUS; DOGS; FACTOR IX; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; GENETIC VECTORS; HEMOPHILIA B; MICE; PORTAL VEIN;

EID: 84922059387     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-62703-761-7_27     Document Type: Article

References (35)

1. Sarkar R, Xiao W, Kazazian HH Jr (2003) A single adeno-Associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype. J Thromb Haemost 1:220-226
2. Jiang H, Lillicrap D, Patarroyo-White S, Liu T, Qian X, Scallan CD, Powell S, Keller T, McMurray M, Labelle A, Nagy D, Vargas JA, Zhou S, Couto LB, Pierce GF (2006) Multiyear therapeutic benefi t of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs. Blood 108:107-115
3. Markusic DM (2012) Liver-directed adenoassociated viral gene therapy for hemophilia. J Genet Syndr Gene Ther S1:009
4. Mingozzi F, Hasbrouck NC, Basner-Tschakarjan E, Edmonson SA, Hui DJ, Sabatino DE, Zhou S, Wright JF, Jiang H, Pierce GF, Arruda VR, High KA (2007) Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood 110:2334-2341
5. Mount JD, Herzog RW, Tillson DM, Goodman SA, Robinson N, McCleland ML, Bellinger D, Nichols TC, Arruda VR, Lothrop CD Jr, High KA (2002) Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy. Blood 99:2670-2676
6. Snyder RO, Miao C, Meuse L, Donahue BA, Lin H-F, Stafford DW, Patel S, Thompson A, Nichols T, Bellinger D, Read M, Brinkhous KM, Kay MA (1999) Correction of hemophilia B in canine and murine models using recombinant adeno-Associated viral vectors. Nat Med 5:64-70
7. Nichols TC, Raymer RA, Franck HW, Merricks EP, Bellinger DA, DeFriess N, Margaritis P, Arruda VR, Kay MA, High KA (2010) Prevention of spontaneous bleeding in dogs with haemophilia A and haemophilia B. Haemophilia 16(Suppl 3):19-23
8. Niemeyer GP, Herzog RW, Mount J, Arruda VR, Tillson DM, Hathcock J, van Ginkel FW, High KA, Lothrop CD Jr (2009) Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy. Blood 113:797-806
9. Sabatino DE, Lange AM, Altynova ES, Sarkar R, Zhou S, Merricks EP, Franck HG, Nichols TC, Arruda VR, Kazazian HH Jr (2011) Effi cacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors. Mol Ther 19:442-449
10. Annoni A, Brown BD, Cantore A, Sergi LS, Naldini L, Roncarolo MG (2009) In vivo delivery of a microRNA-regulated transgene induces antigen-specifi c regulatory T cells and promotes immunologic tolerance. Blood 114:5152-5161
11. Cao O, Dobrzynski E, Wang L, Nayak S, Mingle B, Terhorst C, Herzog RW (2007) Induction and role of regulatory CD4+CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer. Blood 110:1132-1140
12. Hoffman BE, Martino AT, Sack BK, Cao O, Liao G, Terhorst C, Herzog RW (2011) Nonredundant roles of IL-10 and TGF-beta in suppression of immune responses to hepatic AAV-factor IX gene transfer. Mol Ther 19:1263-1272
13. LoDuca PA, Hoffman BE, Herzog RW (2009) Hepatic gene transfer as a means of tolerance induction to transgene products. Curr Gene Ther 9:104-114
14. Nathwani AC, Tuddenham EG, Rangarajan S, Rosales C, McIntosh J, Linch DC, Chowdary P, Riddell A, Pie AJ, Harrington C, O'Beirne J, Smith K, Pasi J, Glader B, Rustagi P, Ng CY, Kay MA, Zhou J, Spence Y, Morton CL, Allay J, Coleman J, Sleep S, Cunningham JM, Srivastava D, Basner-Tschakarjan E, Mingozzi F, High KA, Gray JT, Reiss UM, Nienhuis AW, Davidoff AM (2011) Adenovirus-Associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365:2357-3265
15. Mingozzi F, High KA (2011) Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat Rev Genet 12:341-355
16. Manno CS, Pierce GF, Arruda VR, Glader B, Ragni M, Rasko JJ, Ozelo MC, Hoots K, Blatt P, Konkle B, Dake M, Kaye R, Razavi M, Zajko A, Zehnder J, Rustagi PK, Nakai H, Chew A, Leonard D, Wright JF, Lessard RR, Sommer JM, Tigges M, Sabatino D, Luk A, Jiang H, Mingozzi F, Couto L, Ertl HC, High KA, Kay MA (2006) Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response. Nat Med 12:342-347
17. Cooper M, Nayak S, Hoffman BE, Terhorst C, Cao O, Herzog RW (2009) Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer. Hum Gene Ther 20:767-776
18. Nathwani AC, Rosales C, McIntosh J, Rastegarlari G, Nathwani D, Raj D, Nawathe S, Waddington SN, Bronson R, Jackson S, Donahue RE, High KA, Mingozzi F, Ng CY, Zhou J, Spence Y, McCarville MB, Valentine M, Allay J, Coleman J, Sleep S, Gray JT, Nienhuis AW, Davidoff AM (2011) Long-term safety and effi cacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther 19: 876-885
19. Wang L, Takabe K, Bidlingmaier SM, Verma IM (1999) Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. Proc Natl Acad Sci USA 96: 3906-3910
20. Mingozzi F, Schuttrumpf J, Arruda VR, Liu Y, Liu YL, High KA, Xiao W, Herzog RW (2002) Improved hepatic gene transfer by using an adeno-Associated virus serotype 5 vector. J Virol 76:10497-10502
21. Markusic DM, Herzog RW, Aslanidi GV, Hoffman BE, Li B, Li M, Jayandharan GR, Ling C, Zolotukhin I, Ma W, Zolotukhin S, Srivastava A, Zhong L (2010) High-effi ciency transduction and correction of murine hemophilia B using AAV2 vectors devoid of multiple surface-exposed tyrosines. Mol Ther 18: 2048-2056
22. Sack BK, Merchant S, Markusic DM, Nathwani AC, Davidoff AM, Byrne BJ, Herzog RW (2012) Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy. PLoS One 7:e37671
23. Wu Z, Sun J, Zhang T, Yin C, Yin F, Van Dyke T, Samulski RJ, Monahan PE (2008) Optimization of self-complementary AAV vectors for liver-directed expression results in sustained correction of hemophilia B at low vector dose. Mol Ther 16:280-289
24. Cao O, Hoffman BE, Moghimi B, Nayak S, Cooper M, Zhou S, Ertl HC, High KA, Herzog RW (2009) Impact of the underlying mutation and the route of vector administration on immune responses to factor IX in gene therapy for hemophilia B. Mol Ther 17: 1733-1742
25. Sabatino DE, Nichols TC, Merricks E, Bellinger DA, Herzog RW, Monahan PE (2012) Animal models of hemophilia. Prog Mol Biol Transl Sci 105:151-209
26. Margaritis P, Roy E, Aljamali MN, Downey HD, Giger U, Zhou S, Merricks E, Dillow A, Ezban M, Nichols TC, High KA (2009) Successful treatment of canine hemophilia by continuous expression of canine FVIIa. Blood 113:3682-3689
27. Evans JP, Brinkhous KM, Brayer GD, Reisner HM, High KA (1989) Canine hemophilia B resulting from a point mutation with unusual consequences. Proc Natl Acad Sci USA 86:10095-10099
28. Herzog R, Arruda VR, Fischer TH, Read MS, Nichols TC, High KA (2000) Absence of circulating factor IX antigen in hemophilia B dogs of the UNC-Chapel Hill colony. Thromb Haemost 84:352-354
29. Russell KE, Olsen EH, Raymer RA, Merricks EP, Bellinger DA, Read MS, Rup BJ, Keith JC Jr, McCarthy KP, Schaub RG, Nichols TC (2003) Reduced bleeding events with subcutaneous administration of recombinant human factor IX in immune-tolerant hemophilia B dogs. Blood 102:4393-4398
30. Russell KE, Read MS, Bellinger DA, Leitermann K, Rup BJ, McCarthy KP, Keith JC Jr, Khor SP, Schaub RG, Nichols TC (2001) Intratracheal administration of recombinant human factor IX (BeneFix) achieves therapeutic levels in hemophilia B dogs. Thromb Haemost 85:445-449
31. Brinkhous KM, Sigman JL, Read MS, Stewart PF, McCarthy KP, Timony GA, Leppanen SD, Rup BJ, Keith JC Jr, Garzone PD, Schaub RG (1996) Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B. Blood 88: 2603-2610
32. Shapiro AD, Ragni MV, Valentino LA, Key NS, Josephson NC, Powell JS, Cheng G, Thompson AR, Goyal J, Tubridy KL, Peters RT, Dumont JA, Euwart D, Li L, Hallen B, Gozzi P, Bitonti AJ, Jiang H, Luk A, Pierce GF (2012) Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in hemophilia B patients. Blood 119:666-672
33. Roth DA, Kessler CM, Pasi KJ, Rup B, Courter SG, Tubridy KL (2001) Human recombinant factor IX: safety and effi cacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood 98:3600-3606
34. Arruda VR, Fields PA, Milner R, Wainwright L, De Miguel MP, Donovan PJ, Herzog RW, Nichols TC, Biegel JA, Razavi M, Dake M, Huff D, Flake AW, Couto L, Kay MA, High KA (2001) Lack of germline transmission of vector sequences following systemic administration of recombinant AAV-2 vector in males. Mol Ther 4:586-592
35. Nichols TC, Franck HWG, Franck C, Raymer RA, Merricks EP (2012) Sensitivity of whole blood clotting time and activated partial thromboplastin time for canine factor IX. J Thromb Haemost 10:474-476